Reference no: EM132463729

Carl Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Carl's fiscal year ends on December 31. Its financial statements are issued in April and policies are based on ASPE.

2021

Point a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $20,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees.

Point b. On October 1, borrowed $17 million cash from Second Commercial Bank under the line of credit and issued a five-month promissory note. Interest at the prime rate of 9% was payable at maturity. Management planned to issue 10-year bonds in February to repay the note.

Point c. Received $3,100 of refundable deposits in December for reusable containers used to transport and store chemical-based products.

Point d. For the September-December period, sales on account totaled $4,190,000. The state sales tax rate is 3% and the local sales tax rate is 3%. (This is a summary journal entry for the many individual sales transactions for the period.)

Point e. Recorded the adjusting entry for accrued interest.

2022

Point f. In March, paid the entire amount of the note on its March 1 due date, using proceeds from a February issuance of $12.8 million of 10- year bonds at face value, along with other available cash.

Point g. Half of the storage containers covered by refundable deposits were returned in March 2022. The remaining containers will not be returned.

Required:

Question 1. Prepare the appropriate journal entries for items a-g.

Question 2. Prepare the current and long-term liability sections of the December 31, 2021, balance sheet. Trade accounts payable on that date were $283,000. Provide re-financing related note disclosure also.

Question 3) How would your answer to part 2) change if Mosaic used IFRS as its accounting platform?